BC
IMNM icon

Birchview Capital’s Immunome IMNM Stock Holding History

Birchview Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Sell
50,000
-80,000
-62% -$1.78M 0.62% 39
2025
Q4 		$2.79M Buy
130,000
+25,000
+24% +$439K 1.63% 19
2025
Q3 		$1.23M Buy
105,000
+45,000
+75% +$448K 0.93% 28
2025
Q2 		$558K Buy
+60,000
New +$492K 0.55% 41

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Birchview Capital's IMNM Position: Q1 2026 in Review

Birchview Capital reduced its Immunome (IMNM) stake by 62% in Q1 2026, selling an estimated $1.78M and leaving 50,000 shares worth $1.09M. The position accounts for 0.62% of the portfolio, ranked #39.

Birchview Capital first reported a position in IMNM in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.79M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Birchview Capital held 50,000 shares of Immunome worth $1.09M as of Q1 2026.
  • Birchview Capital sold 80,000 Immunome shares in Q1 2026, an estimated $1.78M.
  • Immunome made up 0.62% of Birchview Capital's portfolio in Q1 2026, its #39 holding.
  • Birchview Capital first reported a position in Immunome in Q2 2025 and has held it in 4 quarters since.
  • Birchview Capital's Immunome position peaked at $2.79M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.